Search the Newsreel

Twist Bioscience Corp stock hits 52-week high at 106.58 USD

Twist Bioscience Corp (TWST) reached a 52-week high of $106.58, with its stock currently trading at $103.80. The company has shown a robust 267.22% increase over the past year and recently reported fiscal third-quarter 2026 revenue of $118.4 million, exceeding expectations. Despite the strong …

Twist Bioscience's 24 New Hires Set to Receive Stock Awards

Twist Bioscience (NASDAQ: TWST) announced it will grant a total of 44,434 restricted stock units (RSUs) to 24 new employees as an inducement to employment. These grants are made under the company's Amended and Restated Inducement Equity Incentive Plan, in compliance with Nasdaq Listing …

Twist Bioscience Corporation Stock 12‑Month Price Target Raised to $109.67, Implies 20% Upside

Analysts have raised the 12-month average price target for Twist Bioscience Corporation (TWST) stock to $109.67, up from $104. This new target suggests a potential 20% upside from its July 31st closing price, with individual forecasts ranging from $85 to $120 per share. The …

Twist Bioscience Corp (TWST) (Q3 2026) Earnings Call Highlights: Record Revenue and AI-Driven ...

Twist Bioscience Corp (TWST) announced record revenue of $118.4 million in Q3 2026, marking its 14th consecutive quarter of growth, with AI-enabled drug discovery orders expected to achieve triple-digit growth. The company improved its gross margin to 52.8% and expects to reach adjusted EBITDA …

Twist Bioscience Corp 2026: Revenue $118.38M, EPS ($0.56) — 10-Q Summary

Twist Bioscience Corp reported its 2026 quarterly results, showing a 23.2% increase in revenue to $118.38M compared to the prior year, driven by growth in DNA synthesis, protein products, and NGS applications. Despite increased revenue, the company's net loss widened to ($35.05M) with a …

TWIST BIOSCIENCE CORP : LEERINK PARTNERS RAISES TARGET PRICE $120.00 FROM $110.00

Leerink Partners has raised its target price for Twist Bioscience Corp (TWST.O) from $110.00 to $120.00. This indicates an increased positive outlook from the analytical firm regarding the company's future stock performance.

Twist Bioscience Jumps as Raised 2026 Outlook Appears to Drive Buying

Twist Bioscience (TWST) stock jumped 10.4% following its fiscal third-quarter update, which included a raised full-year 2026 revenue outlook and continued progress toward adjusted EBITDA breakeven. The company increased its revenue guidance to $456 million-$457 million and highlighted improving execution in its synthetic biology …

Twist Bioscience (TWST) insider Paula Green files to sell 1,133 shares

Twist Bioscience insider Paula Green has filed a Form 144 to sell 1,133 shares of common stock through Fidelity Brokerage Services LLC on August 3, 2026. These shares are linked to restricted stock vesting on July 31, 2026, as compensation. The filing also details …

Twist Bioscience Reports 12.0% Wider Q3 2026 Loss at -$0.56/Share

Twist Bioscience (NASDAQ:TWST) reported a wider-than-expected Q3 2026 diluted loss of $0.56 per share, missing analyst estimates despite achieving robust revenue growth of 23.3% to $118.4 million. The company's net loss reached $35.1 million due to continued investments in capacity expansion and market penetration. …

Twist Bioscience stock falls 5% on earnings miss despite revenue beat

Twist Bioscience Corporation (NASDAQ:TWST) reported third-quarter fiscal 2026 results with a miss on earnings per share but a beat on revenue expectations, leading to a 4.97% drop in pre-market trading. The company achieved a record revenue of $118.4 million, marking its 14th consecutive quarter …

Press Release: Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience has announced its financial results for the third quarter of fiscal year 2026. The company reported significant revenue growth and provided updates on its operational progress and future outlook. Key highlights include strong performance across its various product lines and strategic advancements …

Twist Bioscience Shares Decline Following Quarterly Earnings Miss

Twist Bioscience (NASDAQ:TWST) Posts Earnings Results, Misses Estimates By $0.07 EPS

Twist Bioscience (NASDAQ:TWST) Shares Gap Down on Disappointing Earnings

Twist Bioscience (TWST) Earnings Date and Reports 2026 $TWST

Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates

Should Twist Bioscience’s US$17.05 Million Class Action Settlement Reshape Risk Perceptions for TWST Investors?

Twist Bioscience (TWST) recently held a hearing for a proposed US$17.05 million cash settlement to resolve a securities class action lawsuit. This settlement, if approved, would address past legal risks related to capital-raising activities for the period between December 2018 and November 2022. While …

Twist Bioscience Reports Monday With Breakeven Timeline Now Three Quarters Away

Twist Bioscience (TWST) is set to report fiscal third-quarter earnings, with investors focusing on the company's path to profitability and its role in AI-enabled drug discovery after a significant 154% surge in its stock price over the past year. Analysts have a largely bullish …

Twist Bioscience earnings loom as profitability path under scrutiny

Twist Bioscience Corp. is preparing to report its fiscal third-quarter results, with analysts expecting a loss of 49 cents per share on revenue of $114.6 million, indicating sequential improvement and significant year-over-year growth. The company's stock has rallied 154% over the past year, driven …

Twist Bioscience Number of Employees 2026 | Employee Count & Headcount Data

Twist Bioscience Corp. (TWST) had approximately 1,065 employees worldwide as of March 2026, representing a 5.0% growth from 2023. The company is actively hiring, with 133 job postings in 2026, and its workforce is concentrated in the United States, with a growing presence in …

Twist Bioscience Market Sentiment

This article provides an overview of market sentiment for Twist Bioscience (TWST), detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" analyst consensus, a 25.7% declining short float, and a bullish options flow with a 0.52 Put/Call ratio, despite …

TWST|Twist Bioscience Corp|Price:85.490|Chg%:-3.060

Twist Bioscience Corp (TWST) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly valued. Analysts rate it as a Strong Buy with a target price of $94.33. Despite recent weak market performance, the stock is expected to trend upwards in …

Twist Bioscience Corp (TWST) executive sells 2,238 shares in tax sell-to-cover

Twist Bioscience Corp's President and COO, Patrick John Finn, sold 2,238 shares of common stock on July 23, 2026, at $93.893 per share. This sale was a non-discretionary "sell to cover" transaction to meet tax withholding obligations related to the vesting of Restricted Stock …

Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market

New research on AI-driven biologics discovery identifies Carterra's high-throughput SPR platforms as central to the Lab-in-the-Loop (LitL) workflow reshaping drug discovery, with Twist Bioscience and Adaptyv Bio pointing to surging demand for Carterra technology SALT LAKE CITY, July 27, 2026--(BUSINESS WIRE)--Carterra®, a leading provider …

Twist Bioscience Corp (TWST) Cash Flow

This article provides a detailed cash flow statement for Twist Bioscience Corp (TWST), covering quarterly data across several fiscal years. It breaks down operating, investing, and financing cash flows, including specifics like net income, capital expenditures, and stock issuance. Additionally, it defines key cash …

Twist Bioscience (TWST) Expected to Post Quarterly Earnings on Monday

Twist Bioscience (TWST) Stock Could Be Overvalued Even After A 261% Run

Twist Bioscience (TWST) Stock Looks Overvalued Even With Strong Growth Hopes

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Twist Bioscience stock has delivered very strong long term gains over the last three years, yet the current valuation screens as expensive on several …

Twist Bioscience Corp (TWST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Twist Bioscience Corp (TWST) by business segment and region, using data updated on April 6. The company's revenue is split between NGS applications and DNA synthesis and protein solutions, with the Americas being the largest regional …

Twist Bioscience (TWST) Surged on Strong Results and AI Drug Discovery Demand

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. …

Form 144 Twist Bioscience Corp For: 23 July By Investing.com

The article announces the filing of Form 144 for Twist Bioscience Corp (TWST) on July 23. This financial disclosure is provided by Investing.com, a platform that regularly publishes such regulatory updates. The Form 144 filing is a notification to the SEC of the intent …

Twist Bioscience Corporation Revenue Breakdown – NASDAQ:TWST

Twist Bioscience Corporation (NASDAQ: TWST) generated $376.57 million USD in revenue last year, with its Next Generation Sequencing Tools segment contributing the most at $208.10 million USD. The United States was the largest regional contributor, accounting for $218.41 million USD of the total revenue.

Insider for TWST (NASDAQ: TWST) files Form 144 for stock sale

An affiliate of Twist Bioscience Corp (TWST) filed a Form 144 to sell 2,238 shares of common stock on July 23, 2026, on NASDAQ, with an indicated value of $210,132.53. These shares relate to restricted stock vesting from July 22, 2026, treated as compensation. …

Twist Bioscience stock trades mixed as revenue grows and losses narrow

Twist Bioscience (TWST) stock shows mixed performance as the company balances strong revenue growth in its synthetic DNA and genomics tools with continued, though narrowing, net losses. Fiscal 2023 saw revenue climb to $245 million, a 40% increase, while net losses decreased to $200 …

ETFs Investing in Twist Bioscience Corp. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Twist Bioscience Corp. The ETFs are sorted by their market value of Twist Bioscience holdings and include details such as weight, issuer, management style, expense ratio, assets under management (AUM), and price …

Twist Bioscience Corporation (TWST): Investor Outlook Reveals 19.3% Revenue Growth and Strong Analyst Support

Twist Bioscience Corporation (TWST) is a prominent player in diagnostics and research, known for its synthetic DNA technology. The company has demonstrated 19.3% revenue growth and maintains strong analyst support with mostly buy ratings, despite facing challenges with negative net income and free cash …